The estimated Net Worth of James E Audia is at least $2.17 million dollars as of 12 May 2020. James Audia owns over 6,100 units of Constellation Pharmaceuticals Inc stock worth over $864,502 and over the last 6 years he sold CNST stock worth over $1,174,185. In addition, he makes $126,772 as Director at Constellation Pharmaceuticals Inc.
Sign up
James Audia CNST stock SEC Form 4 insiders trading
James has made over 5 trades of the Constellation Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 6,100 units of CNST stock worth $305,610 on 12 May 2020.
The largest trade he's ever made was selling 22,500 units of Constellation Pharmaceuticals Inc stock on 6 November 2019 worth over $417,375. On average, James trades about 4,360 units every 20 days since 2018. As of 12 May 2020 he still owns at least 25,434 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of James Audia stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Audia biography
Dr. James E. Audia serves as Director of the Company. Dr. Audia is the president and sole proprietor of Audia Consulting, LLC, a scientific consulting firm which he founded in September 2019. Since November 2019, he has also served as an entrepreneur in residence for Third Rock Ventures, a venture capital firm. Since November 2019 he has also been senior advisor and head of chemistry for Karuna Therapeutics, a publicly traded biopharmaceutical company. Dr Audia has been a member of the Alzheimer’s Association since January 2020. Between August 2017 and October 2019, Dr. Audia served as Executive Director of the Chicago Biomedical Consortium, or CBC, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation. Prior to joining the CBC, Dr. Audia served as our chief scientific officer from January 2011 to July 2017. Prior to joining us as chief scientific officer, Dr. Audia served in a number of roles at Eli Lilly & Company, a global healthcare company, from 1987 until December 2010. From January 2011 to December 2017, Dr. Audia served as a scientific advisor to Sage Therapeutics, Inc., a public biopharmaceutical company. Dr. Audia also serves as a scientific advisor and a member of the board of directors of Ribon Therapeutics, Inc., a private biotechnology company. He received a B.S. and Ph.D. in organic chemistry from the University of South Carolina and completed postdoctoral training at Yale University. Audia’s extensive experience in the biopharmaceutical industry and his prior experience as our chief scientific officer qualify him to serve as a member of our board of directors.
What is the salary of James Audia?
As the Director of Constellation Pharmaceuticals Inc, the total compensation of James Audia at Constellation Pharmaceuticals Inc is $126,772. There are 4 executives at Constellation Pharmaceuticals Inc getting paid more, with Jigar Raythatha having the highest compensation of $2,306,720.
How old is James Audia?
James Audia is 64, he's been the Director of Constellation Pharmaceuticals Inc since 2017. There are no older and 10 younger executives at Constellation Pharmaceuticals Inc.
What's James Audia's mailing address?
James's mailing address filed with the SEC is C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE, MA, 02142.
Insiders trading at Constellation Pharmaceuticals Inc
Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... et Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.
What does Constellation Pharmaceuticals Inc do?
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
What does Constellation Pharmaceuticals Inc's logo look like?
Complete history of James Audia stock trades at Constellation Pharmaceuticals Inc
Constellation Pharmaceuticals Inc executives and stock owners
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jigar Raythatha,
President, Chief Executive Officer, Director -
Emma Reeve,
Chief Financial Officer, Senior Vice President, Treasurer -
Scott Braunstein,
Independent Director -
Mark Goldsmith,
Independent Chairman of the Board -
Robert Tepper,
Independent Director -
James Audia,
Director -
Elizabeth Trehu,
Independent Director -
Steven Hoerter,
Independent Director -
Ronald Aldridge,
IR Contact Officer -
Richard Levy,
Independent Director -
Jeffrey Humphrey,
Chief Medical Officer -
Karen Valentine,
Chief Legal Officer, General Counsel -
Patrick Trojer,
Chief Scientific Officer -
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Iii, ...,
-
Group L Pgoeddel David V Sv...,
-
Group L Pcolumn Group Iii, ...,
-
Rock Ventures Lp Third Rock...,
-
Advisors Llc Orbi Med Globa...,
-
Of The University Of Califo...,
-
Capital, Llc Casdin Partner...,
-
Peter Svennilson,
Director -
Ventures Ii, Lp Spur Capita...,
-
Fund L.P.Topspin Biotech Fu...,
-
Berg Ltd Mountain,
10% owner -
Anthony B Evnin,
Director -
Group L Pcolumn Group Gp, L...,
-
Onco Ltd Precision,
10% owner -
Venture Investments, Llc Al...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Jerry A Hatfield,
Sr. Vice President, Operations -
Michael John Hoffman,
President and CEO -
Daniel Ingram,
Senior V.P., Sales/Marketing -
James Ct Bolton,
Senior Vice President -
James A Lewis,
Director -
Frank J Mechura,
Director -
Angus Smith,
Director -
Donald P Deubel,
SVP, Corporate Technologies -
Christopher Phelan,
VP European Operations -
Walter Stanley Sobon,
Executive VP and CFO -
David J Waksman,
Senior Vice President -
Michael Dudley Mc Daniel,
Director -
John P Neafsey,
Director -
A Alexander Ii Taylor,
Director -
Group L Pcolumn Group Gp, L...,
-
Healthcare Capital Partners...,
-
Adrian Senderowicz,
Chief Medical Officer